



#4

PATENT

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 18 2001

TECH CENTER 1600/2900

In re application : Zuheir L. Audeh et al.
Application No. : 09/848,777
Filed : May 4, 2001
For : COLLOID COMPOSITION FOR SOLID PHASE BIOMOLECULAR
ANALYTICAL, PREPARATIVE AND IDENTIFICATION
SYSTEMS
Attorney's Docket : CBR-001XX

Group Art Unit: 1645

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C. 20231 on

7/18/01By: 

Stanely M. Schurgin
Registration No. 20,979
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the
enclosed references listed on the attached copy of PTO Form #1449. The
paragraph(s) marked below are applicable to this Information Disclosure
Statement.

- [X] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached
Information Disclosure Statement is being filed within three
months of the filing date of the above identified national
application or within three months of the date of entry of the
national stage as set forth in 37 C.F.R. § 1.491 of the above
identified application. Accordingly, applicant(s) believes that
no fee or statement under 37 C.F.R. § 1.97(e) is required.

- [X] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
- [] a statement under 37 CFR § 1.97(e); or
- [] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- [] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(i).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- [] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

- [] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure

Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

ZUHEIL L. AUDEH ET AL.

By: 

Stanely M. Schurgin
Registration No. 20,979
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290
Telecopier: (617) 451-0313

SMS/knr
Enclosure
252475-1

Date: July 12, 2001

Page 1 of 2

Form PTO-1449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

CBR-001XX

09/848,777



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT:

Zuheir L. Audeh et al.

FILING DATE

May 4, 2001

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
	6,197,599	03/06/2001	Chin et al.	436	518	
	6,159,685	12/12/2000	Pinkel et al.	435	6	
	6,146,593	11/14/2000	Pinkel et al.	422	68.1	
	6,110,426	08/29/2000	Shalon et al.	422	68.1	
	6,066,453	05/23/2000	Pinkel et al.	435	6	
	5,830,645	11/03/1998	Pinkel et al.	435	6	
	5,837,196	11/17/1998	Pinkel et al.	422	55	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 00/03037	01/20/2000	WIPO	C12Q	1/68	
WO 99/07892	01/18/1999	WIPO	C12Q	1/68	
WO 98/20353	05/14/1998	WIPO	G01N	33/567	
WO 94/26933	11/24/1994	WIPO	C12Q	1/68	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	Susan B. Yox, RN, EdD, "The Laboratory on a Chip-The Future of Miniaturization and Automation", Laboratory Medicine, Vol. 30, No. 7, PP. 456-461 (1999)
	Pinkel et al., "High Resolution Analysis of DNA Copy Number Variation Using Comparative Genomic Hybridization to Microarrays", Nature Genetics, Vol. 20, PP. 207-211 (1998)
	MacBeath et al., "Printing Proteins as Microarrays for High-Throughput Function Determination", Science, Vol. 289, PP. 1760-1763 (2000)
	Lemieux et al., "Overview of DNA chip technology", Molecular Breeding, Vol. 4, PP. 277-289 (1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: July 12, 2001

Page 2 of 2

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE

(REV. 8-83)

PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

CBR-001XX

09/848,777



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT:

Zuheir L. Audeh et al.

FILING DATE

May 4, 2001

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
	5,807,522	09/15/1998	Brown et al.	422	50	
	5,744,305	04/28/1998	Fodor et al.	435	6	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	Eric S. Lander, "Array of Hope", Nature Genetics Supplement, Vol. 21, PP. 3-61 (1999)
	Haab et al., "Protein Microarrays for Highly Parallel Detection and Quantitation of Specific Proteins and Antibodies in Complex Solutions", Vol. 2 No. 2, 13 Pages, http://genomebiology.com (2001)
	Guo et al., "Oligonucleotide Arrays for High Resolution HLA Typing", Reviews in Immunogenetics, Vol. 1, PP. 220-230 (1999)
	Grace Bio-Labs, "ONCYTE Film-Slides", "HybriWell Sealing System", "HybriSlip Hybridization Covers", "MultiWell Press-to-Seal Arrays", "Grace Bio-Labs-About Grace", "What's New In Our Laboratory", www.gracebio.com (1998)
	Mary Jane Friedrich, "New Chip on the Block-The Arrival of Biochip Technology", Laboratory Medicine, Vol. 30, PP. 179-188 (1999)
	Unknown Author, "Microarray Configuration Formats", Slide show. (1999)
	William J. Cromie, "Identifying Source of Disease-Faulty Proteins Account for Most of the World's Sickness", Harvard University Gazette, Vol. XCVI, No. 3, PP.1 and 4 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.